InsiderTrades.com logo
The "Smart Money" Is Ready for May 1st Are You?
From Stansberry Research   |   Ad
Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.
One Former Wall St. Trader Explains Why…
Elizabeth Bhatt net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Elizabeth Bhatt Biography and Net Worth

Insider of Applied Molecular Transport
Elizabeth Bhatt, Chief Business and Strategy Officer. Ms. Bhatt has served as our Chief Business and Strategy Officer since September 2019. Prior to joining the Company, Ms. Bhatt was at Achaogen, Inc., a biopharmaceutical company, where she was Chief Operating Officer from July 2018 to June 2019 and Chief Business Officer from September 2017 to June 2019. Prior to Achaogen, Ms. Bhatt held various roles at Gilead Sciences, Inc., a biopharmaceutical company, from July 2006 to September 2017, including Vice President, Corporate Development from January 2016 to September 2017 and Senior Director, Corporate Development from May 2011 to December 2015. She has served on the board of directors of Locust Walk Acquisition Corp., a blank-check company, since January 2021. Ms. Bhatt holds a B.A. in Chemistry from Pomona College, an M.S. in Biomedical Sciences from the University of California, San Diego and an M.B.A. from the Kellogg School of Management at Northwestern University. Provided by Tagnifi.

What is Elizabeth Bhatt's net worth?

The estimated net worth of Elizabeth Bhatt is at least $2,367.00 as of July 21st, 2021. Ms. Bhatt owns 9,000 shares of Applied Molecular Transport stock worth more than $2,367 as of April 26th. This net worth estimate does not reflect any other assets that Ms. Bhatt may own. Learn More about Elizabeth Bhatt's net worth.

How do I contact Elizabeth Bhatt?

The corporate mailing address for Ms. Bhatt and other Applied Molecular Transport executives is 1 TOWER PLACE SUITE 850, SOUTH SAN FRANCISCO CA, 94080. Applied Molecular Transport can also be reached via phone at 650-392-0420 and via email at [email protected]. Learn More on Elizabeth Bhatt's contact information.

Has Elizabeth Bhatt been buying or selling shares of Applied Molecular Transport?

Elizabeth Bhatt has not been actively trading shares of Applied Molecular Transport in the last ninety days. Most recently, Elizabeth Bhatt sold 9,000 shares of the business's stock in a transaction on Wednesday, July 21st. The shares were sold at an average price of $36.68, for a transaction totalling $330,120.00. Following the completion of the sale, the insider now directly owns 9,000 shares of the company's stock, valued at $330,120. Learn More on Elizabeth Bhatt's trading history.

Who are Applied Molecular Transport's active insiders?

Applied Molecular Transport's insider roster includes Elizabeth Bhatt (Insider), Shawn Cross (CFO), Bittoo Kanwar (Insider), Helen Kim (Director), David Lamond (Director), Tahir Mahmood (CEO), Randall Mrsny (Insider), and Aaron VanDevender (Director). Learn More on Applied Molecular Transport's active insiders.

Are insiders buying or selling shares of Applied Molecular Transport?

During the last twelve months, insiders at the sold shares 14 times. They sold a total of 1,097,868 shares worth more than $176,549.76. The most recent insider tranaction occured on November, 22nd when CEO Shawn Cross sold 110,802 shares worth more than $17,728.32. Insiders at Applied Molecular Transport own 15.9% of the company. Learn More about insider trades at Applied Molecular Transport.

Information on this page was last updated on 11/22/2023.

Elizabeth Bhatt Insider Trading History at Applied Molecular Transport

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/21/2021Sell9,000$36.68$330,120.009,000View SEC Filing Icon  
4/21/2021Sell9,000$40.51$364,590.009,000View SEC Filing Icon  
See Full Table

Elizabeth Bhatt Buying and Selling Activity at Applied Molecular Transport

This chart shows Elizabeth Bhatt's buying and selling at Applied Molecular Transport by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Applied Molecular Transport Company Overview

Applied Molecular Transport logo
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trials to treat patients with chronic pouchitis, as well as is in Phase II development to treat patients with rheumatoid arthritis. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral and respiratory biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California. As of December 27, 2023, Applied Molecular Transport Inc. operates as a subsidiary of Cyclo Therapeutics, Inc.
Read More

Today's Range

Now: $0.26
Low: $0.26
High: $0.26

50 Day Range

MA: $0.24
Low: $0.16
High: $0.31

2 Week Range

Now: $0.26
Low: $0.13
High: $0.84

Volume

N/A

Average Volume

470,969 shs

Market Capitalization

$10.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.28
The "Smart Money" Is Ready for May 1st Are You?
From Stansberry Research   |   Ad
Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.
One Former Wall St. Trader Explains Why…